Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

BACKGROUND: There is much discussion in the cancer drug development community about how to incorporate molecular tools into early-stage clinical trials to assess target modulation, measure anti-tumor activity, and enrich the clinical trial population for patients who are more likely to benefit. Smal...

Descripción completa

Detalles Bibliográficos
Autores principales: Cloughesy, Tim F, Yoshimoto, Koji, Nghiemphu, Phioanh, Brown, Kevin, Dang, Julie, Zhu, Shaojun, Hsueh, Teli, Chen, Yinan, Wang, Wei, Youngkin, David, Liau, Linda, Martin, Neil, Becker, Don, Bergsneider, Marvin, Lai, Albert, Green, Richard, Oglesby, Tom, Koleto, Michael, Trent, Jeff, Horvath, Steve, Mischel, Paul S, Mellinghoff, Ingo K, Sawyers, Charles L
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2008
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211560/
https://www.ncbi.nlm.nih.gov/pubmed/18215105
http://dx.doi.org/10.1371/journal.pmed.0050008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2211560/
https://www.ncbi.nlm.nih.gov/pubmed/18215105
http://dx.doi.org/10.1371/journal.pmed.0050008

Ejemplares similares